RxDoctor Payments Data

Eric Scardina, MD

Infectious Disease · New York, NYNPI 1376569269

Payments from drug & device makers

$848in general payments, 2019–2025

Across 32 payments — averaging $26.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$291
  • Johnson & Johnson$128
  • Otsuka America Pharmaceutical, Inc.$125
  • Lilly USA, LLC$112
  • Novo Nordisk$85
  • Sanofi-aventis U.S. LLC$49
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$848100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$848 in reported general payments places this provider in the 60th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$188,324
Medicare patients
145
Services billed
2,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala24$112,557
Repatha SureclickEvolocumab135$101,040
MounjaroTirzepatide88$100,364
GenvoyaElviteg/Cob/Emtri/Tenof Alafen25$97,137
IsentressRaltegravir Potassium40$77,822
TriumeqAbacavir/Dolutegravir/Lamivudi13$54,583
OdefseyEmtricitab/Rilpiviri/Tenof Ala16$53,457
CreonLipase/Protease/Amylase17$40,336
Maraviroc27$34,791
EliquisApixaban27$34,789
Etravirine20$27,622
PifeltroDoravirine12$23,994
Praluent PenAlirocumab40$21,485
OzempicSemaglutide14$13,659
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)22$10,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$112$100,36488 claims
Viiv Healthcare CompanyTriumeq$32$54,58313 claims
AbbVieCreon, Armour Thyroid$15$40,90130 claims
Novo NordiskOzempic$85$13,65914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 799 infectious disease providers in New York.

Other infectious disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →